Drugs / REZETAMIG
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06139406 | Dec 2023 → Jan 2026 overdue | non-Hodgkin lymphoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04540796 | Nov 2020 → Sep 2025 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06660563 Background | Oct 2024 → Jan 2026 overdue | non-Hodgkin lymphoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REZETAMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314871 ↗ |
| Known as | JNJ-75348780 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06660563 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314871 ↗ |
| Route | Subcutaneous | “Participants will receive JNJ-75348780 by subcutaneous (SC) administration.” NCT04540796 ↗ |